Interleukin signaling pathway

The "Interleukin release pathway" is **not a single molecule or receptor**, but rather refers to the collection of cellular signaling cascades initiated by the binding of various **interleukins**—a family of cytokines—to their respective cell surface receptors. These pathways play central roles in regulating immune responses, inflammation, cell proliferation and differentiation. Each interleukin has its own unique receptor(s) and downstream signaling mechanisms. For example: - **IL‑6** signals through its receptor complex involving gp130 and activates JAK/STAT3 and MAPK pathways to regulate inflammation and hematopoiesis[2][4][6]. - **IL‑7** acts via the IL‑7 receptor complex using JAK/STAT5 among other effectors to support T-cell development and survival[3]. - **IL‑1α/β** signal through the type I IL‑1 receptor leading to activation of NFκB and MAPK cascades that drive inflammatory gene expression[5]. Dysregulation of these pathways is implicated in numerous diseases including autoimmune disorders, chronic inflammation, cancer, infection susceptibility, among others. Because "Interleukin release pathway" does not refer to any one protein or druggable entity but rather an entire class of related biological processes involving many different molecules with distinct functions—and because it lacks specificity—it should *not* be considered a canonical therapeutic target itself. If you need structured information about specific targets within this system—such as "Interleukin 6", "Interleukin 7", "Interleukin 1 beta", etc.—those should be addressed individually with their own canonical names.[8]

Other names

Interleukin release pathwayInterleukin pathwaysIL signaling pathways